{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:32:52Z","timestamp":1791502372916,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejca.2019.05.024","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T13:28:46Z","timestamp":1562160526000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"special_numbering":"C","title":["Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network"],"prefix":"10.1016","volume":"117","author":[{"given":"C.","family":"Soussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Blonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bijou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Molu\u00e7on-Chabrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Lelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Clavert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Coisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leruez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Touitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Daniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ertault de la Bretonni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"El Yamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2019.05.024_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Bro\u00ebt","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.05.024_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2405019","article-title":"Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell","volume":"22","author":"Montesinos-Rongen","year":"2008","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.ejca.2019.05.024_bib3","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","author":"Bruno","year":"2014","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ejca.2019.05.024_bib4","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2019.05.024_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.05.024_bib6","article-title":"Massive immunoglobulin repertoire bias in primary intraocular lymphomas suggests antigenic selection of the neoplastic cells during lymphomagenesis","volume":"98 S1","author":"Belhouachi","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejca.2019.05.024_bib7","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation","volume":"103","author":"Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.05.024_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.V94.5.1738","article-title":"V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity","volume":"94","author":"Thompsett","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2019.05.024_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejca.2019.05.024_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2019.05.024_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ejca.2019.05.024_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4170.4170","article-title":"Preclinical evaluation of ibrutinib for central nervous system lymphoma","volume":"128","author":"Pouzoulet","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2019.05.024_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","article-title":"Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series","volume":"88","author":"Chamoun","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ejca.2019.05.024_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ejca.2019.05.024_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.ejca.2019.05.024_bib16","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2019.05.024_bib17","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1167\/iovs.06-0031","article-title":"IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma","volume":"48","author":"Cassoux","year":"2007","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ejca.2019.05.024_bib18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ophtha.2016.01.037","article-title":"ISOLD: a new highly sensitive interleukin score for intraocular lymphoma diagnosis","volume":"123","author":"Costopoulos","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ejca.2019.05.024_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","article-title":"Ibrutinib brain distribution: a preclinical study","volume":"81","author":"Goldwirt","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2019.05.024_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2019.05.024_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V130.Suppl_1.830.830","article-title":"Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2019.05.024_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.ejca.2019.05.024_bib23","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ejca.2019.05.024_bib24","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase I study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreo-retinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2019.05.024_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d phase II study of the French LOC network","volume":"128","author":"Ghesquieres","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2019.05.024_bib26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.15009","article-title":"Immune checkpoint inhibition by anti- PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model","volume":"183","author":"Qiu","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2019.05.024_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hon.2440_2","article-title":"CHECKMATE 647: a phase 2, open-label study of Nivolumab in relapsed\/refractory primary central nervous system or relapsed\/refractory primary testicular lymphoma","volume":"35","author":"Nayak","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919303508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919303508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:35Z","timestamp":1760732675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919303508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"alternative-id":["S0959804919303508"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}